Jump to content

User:Adrian Pelkus/sandbox

From Wikipedia, the free encyclopedia
  • Comment: Wikipedia may not be used to advertise your own discoveries
    As another issue, does this even look like an article to you? 🇵🇸‍🇺🇦 FiddleTimtrent FaddleTalk to me 🇺🇦‍🇵🇸 21:04, 6 May 2025 (UTC)
  • Comment: sources are dire and patents confer zero notability. Theroadislong (talk) 21:03, 6 May 2025 (UTC)

Vaporous Hyperoxia Therapy

Vaporous Hyperoxia Therapy **(VHT)** is a FDA cleared wound care modality designed to accelerate the healing of chronic and difficult-to-treat wounds. The therapy utilizes a combination of oxygen-enriched gas and ultrasonically created medicated vapor to create a healing environment that enhances tissue oxygenation and supports cellular regeneration.

1. History and Development

VHT was invented by **Adrian Pelkus** in the early 2000s. Public recognition for the therapy came in a feature article titled *"Fast-forwarding the healing process"*, published in *Today’s Local News* on October 12, 2005, and written by Angela Holman.[^1]

The therapy was developed with the aim of providing a non-invasive, adjunctive solution to existing wound care practices, particularly for patients with diabetic ulcers, pressure sores, and other chronic wounds resistant to standard treatments.

VHT has patents granted in the United States and internationally. These patents detail various systems and methods for delivering therapeutic oxygen and vapor to wounds:

- **US-8241258-B2** – *Wound treatment system and method of use*[^2] - **US-8353882-B1** – *Wound treatment system and method of use*[^3] - **US-8663179-B2** – *Wound treatment system and method of use*[^4]

These patents form the technological foundation for VHT systems currently used in clinical settings.

2. Clinical Validation

A 2024 study led by wound care expert **Dr. David Armstrong** further validated the clinical utility of VHT. The retrospective study, published in *WOUNDS* magazine, analyzed the effects of VHT as an adjunct to standard wound care, reporting improved healing outcomes in chronic wound patients.[^5] This publication marked a significant milestone in the peer-reviewed evaluation of the therapy and was an important step in affirming its clinical relevance.

3. Commercialization

VHT has been commercialized and further developed by **VaporOx**, a medical device company focused on wound care innovation. Under the leadership of **Alan Sage** and **Dr. Dustin Kruse**, the company has worked to expand access to the therapy and integrate it into mainstream clinical practice.

---

4. References

[^1]: Angela Holman, *"Fast-forwarding the healing process"*, Today’s Local News, October 12, 2005. [^2]: *Wound treatment system and method of use*, US8241258B2. Available at: [1](https://patents.google.com/patent/US8241258B2/en) [^3]: *Wound treatment system and method of use*, US8353882B1. Available at: [2](https://patents.google.com/patent/US8353882B1/en) [^4]: *Wound treatment system and method of use*, US8663179B2. Available at: [3](https://patents.google.com/patent/US8663179B2/en) [^5]: Armstrong, D.G. et al. *"Retrospective Analysis of the Effect of Vaporous Hyperoxia Therapy as an Adjunct to Standard Wound Care in Chronic Wounds."* WOUNDS (2024). [4](https://www.hmpgloballearningnetwork.com/site/wounds/original-research/retrospective-analysis-effect-vaporous-hyperoxia-therapy-adjunct)